Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug FP008 enters first human tests for advanced cancers

NCT ID NCT06990698

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 23 times

Summary

This early-stage study tests a new drug, FP008, in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, 430014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanxi Cancer Hospital

    RECRUITING

    Taiyuan, Shanxi, 030013, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.